HSCA Comments on Senate Finance Committee “Request for Information on Commonsense Policy Options to Lower Drug Prices for Patients”
On behalf of the Healthcare Supply Chain Association (HSCA), which represents the nation’s leading traditional healthcare group purchasing organizations (GPOs), we appreciate the opportunity to provide comments in response to the Senate Finance Committee’s request for information (RFI) on policies to lower drug prices for patients. HSCA supports the committee’s continued efforts to enhance affordability for patients and improve access to high-quality medications, and we welcome the opportunity to share our perspective on how a strong, competitive, and resilient supply chain advances those shared goals.
Click here to view the full response.
Lear MoreHSCA Response to the Centers for Medicare & Medicaid Services Request for Information on Pharmacy Benefit Manager Compensation and Data Collection
On behalf of the Healthcare Supply Chain Association (HSCA), which represents the nation’s leading
traditional healthcare group purchasing organizations (GPOs), we appreciate the opportunity to provide
comments to the Centers for Medicare and Medicaid Services (CMS) regarding pharmacy benefit manager (PBM) business practices.
Click here to view the full response.
Lear MoreHSCA Applauds House Energy and Commerce Committee and Senate HELP Committee for Advancing Bipartisan Biosimilars Legislation that Will Help Increase Access to Safe Medications
Washington, D.C. (July 29, 2026) – The Healthcare Supply Chain Association (HSCA) and its traditional healthcare group purchasing organization (GPO) members commend the U.S. House Committee on Energy and Commerce for unanimously advancing two bipartisan bills that would expand patient access to lower-cost biosimilars: the Expedited Access to Biosimilars Act (H.R. 9661), led by Reps. Nick Langworthy (R-NY) and Kim Schrier (D-WA), and the Biosimilar Red Tape Elimination Act (H.R. 5526), led by Reps. August Pfluger (R-TX) and Greg Landsman (D-OH). This comes after the Senate Health, Education, Labor, and Pensions (HELP) Committee’s recent advancement of two companion bills, the Expedited Access to Biosimilars Act (S.1414), led by Sen. Rand Paul (R-KY), and the Biosimilars Red Tape Elimination Act (S.1954), led by Sens. Mike Lee (R-UT) and Ben Ray Lujan (D-NM).
“Biosimilars are one of the most effective tools for expanding generic competition in the prescription drug marketplace. Biosimilars have the potential to increase patient access to life-saving medications and reduce costs for the entire healthcare system,” said HSCA President and CEO Angie Boliver. “HSCA has long advocated for policies that ensure a pathway to market for biosimilars that prioritize patient safety while encouraging development and uptake. Eliminating outdated, duplicative testing requirements will help patients get faster access to safe, affordable treatments.”
Click here to view the full statement.
Lear MoreHSCA Applauds Ongoing Bipartisan Efforts that Increase Supply Chain Transparency
The Healthcare Supply Chain Association (HSCA) and its traditional healthcare group purchasing organization (GPO) members applaud the ongoing bipartisan Congressional efforts to increase healthcare supply chain transparency for the ultimate benefit of patients. Specifically, we support two bipartisan drug supply chain transparency measures: the Drug Origin Transparency Act, sponsored by Rep. Doris Matsui (D-CA) and Rep. Dan Crenshaw (R-TX), and the Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act, sponsored by Sens. Rick Scott (R-FL) and Kirsten Gillibrand (D-NY).
“HSCA has long advocated for better visibility into upstream healthcare supply chain information. Increasing transparency, such as providing country-of-origin labeling requirements, will help provide critical visibility for traditional healthcare GPOs, providers, and the patients they serve,” said HSCA President and CEO Angie Boliver. “Tracking and labeling of manufacturing sources would help the FDA and stakeholders across the pharmaceutical supply chain anticipate potential supply disruptions and proactively mitigate the effects of shortages.”
Both bills would require drug labels to include the original manufacturer of the product and the original manufacturer of the active pharmaceutical ingredient, and the Drug Origin Transparency Act would further enable the FDA to require more detailed reporting on API suppliers.
“The Drug Origin Transparency Act and CLEAR LABELS Act are critical steps to help ensure American patients have access to safe and effective medications. HSCA and its member GPOs applaud Rep. Matsui, Sen. Scott, and Sen. Gillibrand for leading this effort, and we look forward to continuing to work with Congress to increase transparency in the pharmaceutical supply chain.”
###
About the Healthcare Supply Chain Association (HSCA)
The Healthcare Supply Chain Association (HSCA) represents the nation’s leading healthcare group purchasing organizations (GPOs), which are critical cost-savings partners to America’s hospitals, nursing homes, nursing home pharmacies, clinics, home healthcare providers, and surgery centers. GPOs deliver billions in savings annually to healthcare providers, Medicare and Medicaid, and taxpayers. HSCA and its member GPOs are committed to delivering the best products at the best value to healthcare providers, increasing competition and innovation in the market, and serving as leaders in transparency and accountability. For more information, visit supplychainassociation.org. Follow HSCA on X (Twitter) @HSCA.
Lear MoreHSCA Response to the U.S. Trade Representative’s Section 301 Investigation of Acts, Policies, and Practices of Certain Economies Relating to Structural Excess Capacity and Production in Manufacturing Sectors
On behalf of the Healthcare Supply Chain Association (HSCA), which represents the nation’s leading traditional healthcare group purchasing organizations (GPOs), we appreciate the opportunity to provide comments to the Office of the U.S. Trade Representative on its Section 301 investigation into structural excess capacity and production in manufacturing sectors.
Click here to view the full response.
Lear MoreHSCA Comments on the Centers for Medicare & Medicaid Services Advance Notice of Proposed Rulemaking on Ensuring Safety Through Domestic Security With Made in America PPE and Essential Medicine Procurement by Medicare Participating Hospitals
On behalf of the Healthcare Supply Chain Association (HSCA), which represents the nation’s leading traditional healthcare group purchasing organizations (GPOs), we appreciate the opportunity to provide comments to the Centers for Medicare and Medicaid Services (CMS) regarding its Advance Notice of Proposed Rulemaking (ANPRM) on Ensuring Safety Through Domestic Security With Made in America Personal Protective Equipment (PPE) and Essential Medicine [CMS-1516-ANPRM].
Click here to view the full response.
Lear MoreTestimony of HSCA CEO Angie Boliver before the Subcommittee on Health, House Committee on Energy and Commerce
Thank you for the opportunity to discuss the important role of traditional healthcare group purchasing organizations (GPOs) in lowering costs in the pharmaceutical supply chain.
Click here to view the full response.
Lear More